The Middle East and Africa fibrotic diseases treatment market is projected to register a substantial CAGR of 6.0%in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030. Market Segmentation: Middle East and Africa Fibrotic Diseases Treatment Market, By Treatment (Medication, Organ Transplantation, Oxygen Therapy, Others), Application (Idiopathic Pulmonary Fibrosis, Hepatic Cirrhosis, Renal Fibrosis, Cutaneous Fibrosis, Others), End User (Hospitals, Specialty Clinics, Academic and Research Institutes, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others), Country (South Africa, Saudi Arabia, U.A.E., Egypt, Kuwait, Bahrain Israel, Rest of Middle East and Africa) Some of the major factors contributing to the growth of the Middle East and Africa fibrotic diseases treatment market are: • Technological advancement in the treatment of fibrosis diseases • Increase in the number of people smoking cigarettes Market Players: Some of the key market players in the Middle East and Africa fibrotic diseases treatment market are listed below: • Boehringer Ingelheim International GmbH • AbbVie Inc. • Bristol-Myers Squibb Company • BioMX • Gilead Sciences, Inc. • Teva Pharmaceutical Industries Ltd. • Sandoz International GmbH

1 INTRODUCTION 33 1.1 OBJECTIVES OF THE STUDY 33 1.2 MARKET DEFINITION 33 1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET 33 1.4 LIMITATIONS 35 1.5 MARKETS COVERED 35 2 MARKET SEGMENTATION 37 2.1 MARKETS COVERED 37 2.2 GEOGRAPHICAL SCOPE 38 2.3 YEARS CONSIDERED FOR THE STUDY 39 2.4 CURRENCY AND PRICING 39 2.5 DBMR TRIPOD DATA VALIDATION MODEL 40 2.6 MULTIVARIATE MODELLING 43 2.7 TREATMENT TYPE LIFELINE CURVE 43 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 44 2.9 DBMR MARKET POSITION GRID 45 2.10 MARKET END USER COVERAGE GRID 46 2.11 VENDOR SHARE ANALYSIS 47 2.12 SECONDARY SOURCES 48 2.13 ASSUMPTIONS 48 3 EXECUTIVE SUMMARY 49 4 PREMIUM INSIGHTS 51 4.1 PORTER'S 5 FORCES 52 4.2 PESTEL ANALYSIS 53 5 EPIDEMIOLOGY 54 5.1 INCIDENCE OF ALL BY GENDER 54 5.2 TREATMENT RATE 54 5.3 MORTALITY RATE 54 5.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL 55 5.5 PATIENT TREATMENT SUCCESS RATE 55 6 INDUSTRY INSIGHTS 56 6.1 PATENT ANALYSIS 56 6.2 DRUG TREATMENT RATE BY MATURED MARKETS 56 6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATE 56 6.4 KEY PRICING STRATEGIES 57 6.5 KEY PATIENT ENROLLMENT STRATEGIES 58 7 MERGERS AND ACQUISITIONS 60 7.1 LICENSING: 60 7.2 COMMERCIALIZATION AGREEMENTS 60 8 PIPELINE ANALYSIS 61 8.1 PHASE 1 61 8.2 PHASE 2 61 8.3 PHASE 3 61 9 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET, REGULATIONS 62 9.1 FDA APPROVALS 62 9.2 EMA APPROVALS 63 10 MARKET OVERVIEW 64 10.1 DRIVERS 66 10.1.1 RISING PREVALENCE OF FIBROTIC DISEASES 66 10.1.2 INCREASE IN THE NUMBER OF PEOPLE SMOKING CIGARETTES 66 10.1.3 TECHNOLOGICAL ADVANCEMENT IN THE TREATMENT OF FIBROSIS DISEASES 67 10.2 RESTRAINTS 67 10.2.1 HIGH COST OF MEDICATION AND TREATMENTS 67 10.2.2 LACK OF EFFECTIVE BIOMARKERS AND DIAGNOSTIC TOOLS FOR EARLY DETECTION AND MONITORING OF FIBROTIC DISEASES 67 10.3 OPPORTUNITIES 68 10.3.1 RISING RESEARCH AND DEVELOPMENT ACTIVITIES 68 10.3.2 DEVELOPMENT OF NEW AND MORE EFFECTIVE THERAPIES FOR FIBROTIC DISEASES 68 10.4 CHALLENGES 69 10.4.1 THE COMPLEX AND MULTIFACTORIAL NATURE OF FIBROTIC DISEASES. 69 10.4.2 HIGH RATE OF FAILURE IN CLINICAL TRIALS FOR FIBROTIC DISEASES, WHICH CAN RESULT IN SIGNIFICANT COSTS AND DELAYS IN DRUG DEVELOPMENT 69 11 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET: BY TREATMENT 70 11.1 OVERVIEW 71 11.2 MEDICATION 73 11.2.1 INTEDANIB (OFEV) 74 11.2.2 PIRFENIDONE (ESBRIET) 74 11.3 ORGAN TRANSPLANTATION 74 11.4 OXYGEN THERAPY 75 11.5 OTHERS 76 12 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION 77 12.1 OVERVIEW 78 12.2 IDIOPATHIC PULMONARY FIBROSIS 81 12.3 HEPATIC CIRRHOSIS 81 12.4 RENAL FIBROSIS 82 12.5 CUTANEOUS FIBROSIS 83 12.6 OTHERS 84 13 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET, BY END USER 85 13.1 OVERVIEW 86 13.2 HOSPITALS 89 13.3 SPECIALTY CLINICS 90 13.4 ACADEMIC AND RESEARCH INSTITUTES 90 13.5 OTHERS 91 14 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL 92 14.1 OVERVIEW 93 14.2 HOSPITAL PHARMACY 96 14.3 RETAIL PHARMACY 96 14.4 OTHERS 97 15 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET, BY REGION 98 15.1 MIDDLE EAST AND AFRICA 99 15.1.1 SOUTH AFRICA 105 15.1.2 SAUDI ARABIA 107 15.1.3 U.A.E 109 15.1.4 EGYPT 111 15.1.5 KUWAIT 113 15.1.6 ISRAEL 115 15.1.7 BAHRAIN 117 15.1.8 REST OF MIDDLE EAST AND AFRICA 119 16 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET, COMPANY LANDSCAPE 120 16.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 120 17 SWOT ANALYSIS 121 18 COMPANY PROFILE 122 18.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 122 18.1.1 COMPANY SNAPSHOT 122 18.1.2 REVENUE ANALYSIS 122 18.1.3 COMPANY SHARE ANALYSIS 123 18.1.4 PRODUCT PORTFOLIO 123 18.1.5 RECENT DEVELOPMENTS 123 18.2 GENENTECH, INC. 124 18.2.1 COMPANY SNAPSHOT 124 18.2.2 COMPANY SHARE ANALYSIS 124 18.2.3 PRODUCT PORTFOLIO 125 18.2.4 RECENT DEVELOPMENTS 125 18.3 SANDOZ INTERNATIONAL GMBH 126 18.3.1 COMPANY SNAPSHOT 126 18.3.2 COMPANY SHARE ANALYSIS 126 18.3.3 PRODUCT PORTFOLIO 127 18.3.4 RECENT DEVELOPMENTS 127 18.4 TEVA PHARMACEUTICAL INDUSTRIES LTD. 128 18.4.1 COMPANY SNAPSHOT 128 18.4.2 REVENUE ANALYSIS 128 18.4.3 COMPANY SHARE ANALYSIS 129 18.4.4 PRODUCT PORTFOLIO 129 18.4.5 RECENT DEVELOPMENTS 129 18.5 ACCORD HEALTHCARE U.S. 130 18.5.1 COMPANY SNAPSHOT 130 18.5.2 COMPANY SHARE ANALYSIS 130 18.5.3 PRODUCT PORTFOLIO 131 18.5.4 RECENT DEVELOPMENTS 131 18.6 ABBVIE INC. 132 18.6.1 COMPANY SNAPSHOT 132 18.6.2 REVENUE ANALYSIS 132 18.6.3 PRODUCT PORTFOLIO 133 18.6.4 RECENT DEVELOPMENTS 133 18.7 ALPINE IMMUNE SCIENCES 134 18.7.1 COMPANY SNAPSHOT 134 18.7.2 REVENUE ANALYSIS 134 18.7.3 PRODUCT PORTFOLIO 135 18.7.4 RECENT DEVELOPMENTS 135 18.8 BELLBROOK LABS 136 18.8.1 COMPANY SNAPSHOT 136 18.8.2 PRODUCT PORTFOLIO 136 18.8.3 RECENT DEVELOPMENTS 136 18.9 BIOMX 137 18.9.1 COMPANY SNAPSHOT 137 18.9.2 REVENUE ANALYSIS 137 18.9.3 PRODUCT PORTFOLIO 138 18.9.4 RECENT DEVELOPMENTS 138 18.10 BRISTOL-MYERS SQUIBB COMPANY 139 18.10.1 COMPANY SNAPSHOT 139 18.10.2 REVENUE ANALYSIS 139 18.10.3 PRODUCT PORTFOLIO 140 18.10.4 RECENT DEVELOPMENTS 140 18.11 CAMBER PHARMACEUTICALS, INC. 141 18.11.1 COMPANY SNAPSHOT 141 18.11.2 PRODUCT PORTFOLIO 141 18.11.3 RECENT DEVELOPMENTS 141 18.12 ENVEDA 142 18.12.1 COMPANY SNAPSHOT 142 18.12.2 PRODUCT PORTFOLIO 142 18.12.3 RECENT DEVELOPMENTS 142 18.13 GILEAD SCIENCES, INC. 143 18.13.1 COMPANY SNAPSHOT 143 18.13.2 REVENUE ANALYSIS 143 18.13.3 PRODUCT PORTFOLIO 144 18.13.4 RECENT DEVELOPMENTS 144 18.14 INTERCEPT PHARMACEUTICALS, INC. 145 18.14.1 COMPANY SNAPSHOT 145 18.14.2 REVENUE ANALYSIS 145 18.14.3 PRODUCT PORTFOLIO 146 18.14.4 RECENT DEVELOPMENTS 146 18.15 KITHER BIOTECH S.R.L. 147 18.15.1 COMPANY SNAPSHOT 147 18.15.2 PRODUCT PORTFOLIO 147 18.15.3 RECENT DEVELOPMENTS 147 18.16 PHARMAXIS LTD 148 18.16.1 COMPANY SNAPSHOT 148 18.16.2 REVENUE ANALYSIS 148 18.16.3 PRODUCT PORTFOLIO 149 18.16.4 RECENT DEVELOPMENTS 149 18.17 REDX PHARMA PLC. 150 18.17.1 COMPANY SNAPSHOT 150 18.17.2 REVENUE ANALYSIS 150 18.17.3 PRODUCT PORTFOLIO 151 18.17.4 RECENT DEVELOPMENTS 151 18.18 VERONA PHARMA PLC 152 18.18.1 COMPANY SNAPSHOT 152 18.18.2 REVENUE ANALYSIS 152 18.18.3 PRODUCT PORTFOLIO 153 18.18.4 RECENT DEVELOPMENTS 153 19 QUESTIONNAIRE 154 20 RELATED REPORTS 157